ZFHX3 and non-small cell lung carcinoma: ZFHX3 mutations were also associated with a significant survival benefit across all patients (Fig. 7G), and were most common in colorectal cancer patients, followed by bladder cancer, melanoma, and NSCLC patients (Fig. 7H).